Cargando…
ID1对非小细胞肺癌EGFR-TKI耐药的影响
BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) presents the highest morbidity and mortality among malignant tumors worldwide. The overall effective rate of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is 30% to 40%, and PFS (progression-free sruvival) is 12 mon...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973454/ https://www.ncbi.nlm.nih.gov/pubmed/27978873 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.12.10 |